國家衛生研究院 NHRI:Item 3990099045/8696
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 855577      Online Users : 1228
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/8696


    Title: CARMA3 represses metastasis suppressor NME2 to promote lung cancer stemness and metastasis
    Authors: Chang, YW;Chiu, CF;Lee, KY;Hong, CC;Wang, YY;Cheng, CC;Jan, YH;Huang, MS;Hsiao, M;Ma, JT;Su, JL
    Contributors: National Institute of Cancer Research
    Abstract: RATIONALE: CARD recruited membrane associated protein 3 (CARMA3) is a novel scaffold protein that regulates NF-kappaB activation; however, the underlying mechanism of CARMA3 in lung cancer stemness and metastasis remains largely unknown. OBJECTIVES: To investigate the molecular mechanisms underlying the involvement of CARMA3 in non-small cell lung cancer progression. METHODS: The expression levels of CARMA3 and NME2 in a cohort of lung cancer patients (n = 91) were examined by immunohistochemistry staining and assessed by Kaplan-Meier survival analysis. The effects of CARMA3, miR-182 and NME2 on cancer stemness and metastasis were measured in vitro and in vivo. Chromatin immunoprecipitation and luciferase reporter assays were performed to determine the mechanisms of NF-kappaB-driven miR-182 expression and NME2 regulation. MEASUREMENTS AND MAIN RESULTS: We observed that CARMA3 inversely correlated with NME2 expression in lung cancer patients (Pearson correlation coefficient: R = - 0.24, P = 0.022). NME2 levels were significantly decreased in tumor tissues compared with adjacent normal lung tissues (P < 0.001), and lung cancer patients with higher levels of NME2 had longer survival outcomes (overall survival, P < 0.01; disease-free survival, P < 0.01). Mechanistically, CARMA3 promoted cell motility by reducing the level of NME2 through the NF-kappaB/miR-182 pathway and by increasing cancer stem cell properties and metastasis in lung cancer. CONCLUSIONS: We identified a novel mechanism of CARMA3 in lung cancer stemness and metastasis through the negative regulation of NME2 by NF-kappaB-dependent induction of miR-182. Our findings provide an attractive strategy for targeting the CARMA3/NF-kappaB/miR-182 pathway as a potential treatment for lung cancer.
    Date: 2015-07
    Relation: American Journal of Respiratory and Critical Care Medicine. 2015 Jul;192(1):64-75.
    Link to: http://dx.doi.org/10.1164/rccm.201411-1957OC
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1073-449X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000357838800013
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84937219274
    Appears in Collections:[Jen-Liang Su] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB25906011.pdf6458KbAdobe PDF611View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback